TECX Inc.
TECX scores 29.5 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Moderate penalties (-6.4 points) reflect identified risk factors. The overall score balances these against the stock's fundamental strengths.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| TECX | 29.5 | N/A | 0.0% | 0.0% | $425M |
| CFBK | 44.4 | 11.6 | 3.1% | 13.7% | N/A |
| AIOT | 36.0 | N/A | 0.0% | -7.4% | N/A |
| STRT | 31.0 | 13.5 | 5.1% | 4.6% | $381M |
| IMNM | 30.7 | N/A | -35.5% | N/A | $2.0B |
| MRAM | 29.4 | N/A | -21.0% | -0.9% | $256M |
| GT | 24.7 | N/A | -3.2% | -9.4% | $2.4B |
| ESOA | 19.5 | 106.4 | 16.8% | 0.5% | N/A |
| UXIN | 19.2 | N/A | 45.0% | -10.7% | N/A |
| IPX | 10.1 | N/A | 0.0% | 0.0% | N/A |
| SKYX | 9.5 | N/A | 46.8% | -39.1% | N/A |
| PCT | 2.4 | N/A | 0.0% | -4036.3% | N/A |
| ZJYL | 0.7 | 18.5 | -12.0% | 5.8% | N/A |
| TDOG | 0.2 | N/A | N/A | N/A | N/A |
| VAVX | 0.2 | N/A | N/A | N/A | N/A |
| TMUSZ | 0.2 | N/A | N/A | N/A | N/A |
| Sector Average | 11.1 | 37.5 | 5.6% | -547.1% | — |
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Stock is losing momentum near highs. The 200-day SMA is flattening or beginning to turn. Historically, this stage precedes distribution.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| Operating Income | $-22M | $-22M | $-18M | $-14M |
| Net Income | $-19M | $-20M | $-16M | $-12M |
| EPS (Diluted) | $-1.02 | $-1.07 | $-0.93 | $-0.84 |
| Gross Margin | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $38.04 | $171.36 | 127.3% | Wide |
| 2022 | $6.72 | $49.80 | 152.4% | Wide |
| 2023 | $6.84 | $23.16 | 108.8% | Wide |
| 2024 | $12.12 | $53.41 | 126% | Wide |
| 2025 | $13.70 | $61.07 | 126.7% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.